Depression can make ordinary tasks feel neurologically expensive. Getting out of bed, concentrating at work, answering messages, or enjoying time with people you love may require more effort than you can explain.
If you are considering medication management in New Haven, you may be wondering: Which antidepressant is right for me? Should you start with an SSRI, an SNRI, bupropion, mirtazapine, or something else?
At Light-tunnel Behavioral Health Services Inc. in New Haven, medication decisions are individualized around your symptoms, medical history, other medications, previous treatment response, priorities, and budget. Our psychiatric providers, including Dr. Omolola Aragbada, PMHNP-BC, can help you compare options without reducing your experience to a checklist.
First: What Antidepressants Can and Cannot Do
Antidepressants do not simply “add happiness.” They influence communication among neural circuits involved in mood, motivation, sleep, attention, pain, and emotional regulation.
Think of depression as a city whose transportation network has become congested. Some routes may be underactive, while others are stuck in repetitive loops of rumination, hopelessness, or avoidance. Medication may help improve traffic flow, but therapy, sleep, social support, and meaningful behavioral changes are often part of rebuilding the entire network.
For most antidepressants:
- Early changes may appear within 2–4 weeks.
- A fuller response often requires 6–8 weeks at an effective dose.
- Some people need longer, especially when depression is severe, recurrent, or complicated by anxiety, trauma, substance use, or medical illness.
- A medication should be assessed for both symptom improvement and functional improvement, not only whether you feel less sad.
A large network meta-analysis of 21 antidepressants found that all studied medications were more effective than placebo for acute depression, while differences between medications were generally smaller than the differences in individual tolerability and response (Cipriani et al., 2018).
Antidepressant Classes Compared
| Medication class | How it works | Typical fit | Common concerns | Monitoring and interactions |
|---|---|---|---|---|
| SSRIs: sertraline, escitalopram, fluoxetine, paroxetine, citalopram | Primarily increase serotonin signaling by blocking serotonin reuptake | Often a first choice for depression with anxiety or obsessive symptoms | Nausea, headache, sleep changes, emotional blunting, sexual dysfunction | Review bleeding risk, sodium levels in higher-risk patients, QT risk with citalopram, and other serotonergic medications |
| SNRIs: venlafaxine, duloxetine, desvenlafaxine | Increase serotonin and norepinephrine signaling | Depression with anxiety, fatigue, or certain pain conditions | Nausea, sweating, insomnia, sexual effects, blood-pressure changes | Monitor blood pressure when appropriate; duloxetine requires attention to liver disease and alcohol use |
| Bupropion | Modulates norepinephrine and dopamine reuptake | Low energy, poor concentration, or concern about sexual side effects and weight gain | Anxiety, agitation, insomnia; seizure risk | Avoid in seizure disorders or active eating disorders; review stimulant and activating medications |
| Mirtazapine | Modulates noradrenergic and serotonergic signaling through several receptors | Depression with insomnia, poor appetite, or weight loss | Sleepiness, increased appetite, weight gain, dry mouth | Usually less sexual burden than many SSRIs, but sedation and metabolic effects need review |
| Vortioxetine | Acts at the serotonin transporter and several serotonin receptors | Depression with cognitive symptoms or concern about sexual effects | Nausea, headache, cost or formulary limitations | Review serotonergic combinations and dose adjustments with interacting medications |
| Tricyclics: nortriptyline, amitriptyline, imipramine | Stronger effects on serotonin and norepinephrine, plus other receptor systems | Selected treatment-resistant or chronic cases under specialist care | Dry mouth, constipation, sedation, orthostatic dizziness, weight gain, cardiac toxicity | Greater overdose risk; cardiac history, ECGs, blood levels, and interactions may matter |
| MAOIs: phenelzine, tranylcypromine, selegiline | Inhibit breakdown of several neurotransmitters | Carefully selected treatment-resistant depression | Blood-pressure changes, insomnia, weight effects, serious interaction risks | Requires washout periods and expert review of medications, supplements, and sometimes tyramine-containing foods |
SSRIs: Often the Starting Point
SSRIs are commonly selected because they have a broad evidence base, relatively simple dosing, and lower lethality in overdose than tricyclic antidepressants.
They may suit you when depression occurs alongside:
- Generalized anxiety
- Panic symptoms
- OCD symptoms
- Social anxiety
- Irritability or emotional reactivity
The tradeoff is that SSRIs can cause sexual dysfunction, including reduced desire, delayed orgasm, or difficulty reaching orgasm. Weight effects vary by medication and person, but some people experience weight gain over time.
Paroxetine is more likely to cause discontinuation symptoms because it leaves the body relatively quickly. Fluoxetine has a longer half-life and may produce fewer abrupt withdrawal-like symptoms, although every medication still requires individualized tapering.
SNRIs: Depression Plus Pain, Fatigue, or Low Drive
SNRIs may be useful when depression occurs with fatigue, low motivation, or certain chronic pain conditions. Duloxetine, for example, may be considered when depressive symptoms coexist with some neuropathic or musculoskeletal pain.
Venlafaxine and other SNRIs can cause nausea, sweating, insomnia, sexual side effects, and discontinuation symptoms. Blood pressure monitoring may be appropriate, particularly with venlafaxine or higher doses.
SNRIs can be a reasonable alternative when an SSRI has not helped enough, but switching should be planned carefully. Abruptly stopping venlafaxine, in particular, may lead to dizziness, “electric shock” sensations, irritability, nausea, or flu-like symptoms.
Atypical Antidepressants: Different Tradeoffs
Bupropion
Bupropion is often considered when avoiding sexual dysfunction or weight gain is important. Randomized trials comparing bupropion XL with escitalopram found less orgasm dysfunction and less worsening of sexual functioning with bupropion (Clayton et al., 2006).
It may be a good fit when you experience:
- Low energy or motivation
- Difficulty concentrating
- Sexual side effects from an SSRI
- Concern about weight gain
However, bupropion can feel activating. It may worsen anxiety, agitation, or insomnia in some people. It is generally avoided in patients with seizure disorders or active eating disorders because of seizure risk.
Mirtazapine
Mirtazapine can be helpful when depression is accompanied by insomnia, reduced appetite, or unintended weight loss. Its sedating effect may be useful at bedtime, although excessive morning grogginess can occur.
Compared with bupropion and vortioxetine, mirtazapine has the clearest weight-gain disadvantage. It may still be the most appropriate option for someone who is barely sleeping or eating, but the decision should account for metabolic health and personal priorities.
Vortioxetine
Vortioxetine combines serotonin-transporter effects with activity at several serotonin receptors. Some patients find it relatively favorable for sexual functioning and cognition. Nausea is a common early side effect, and insurance coverage or cost may influence access.
In a randomized switch study, patients with SSRI-associated sexual dysfunction experienced greater improvement in sexual functioning after switching to vortioxetine than after switching to escitalopram, while antidepressant benefit was maintained (Jacobsen et al., 2015).
Tricyclics, MAOIs, and Augmentation
Tricyclic antidepressants and MAOIs can be effective, but their monitoring burden and interaction risks are higher.
Tricyclics may cause anticholinergic effects such as dry mouth, constipation, blurred vision, urinary retention, and confusion. They can also affect heart rhythm and are more dangerous in overdose. Nortriptyline is sometimes preferred over more sedating tricyclics, but specialist oversight remains important.
MAOIs require careful medication reconciliation. They cannot be casually combined with many SSRIs, SNRIs, tricyclics, certain opioids, linezolid, dextromethorphan, or other serotonergic or sympathomimetic substances. Appropriate washout periods are essential.
Augmentation means adding another treatment when an antidepressant has produced partial benefit but not remission. Options may include:
- Aripiprazole or another second-generation antipsychotic
- Lithium
- Thyroid hormone
- A carefully selected second antidepressant
- Structured psychotherapy
- TMS or esketamine in appropriate cases
In the VAST-D randomized clinical trial, remission at 12 weeks occurred in 22.3% of patients who switched to bupropion, 26.9% who augmented with bupropion, and 28.9% who augmented with aripiprazole. Aripiprazole had a modest statistical advantage over switching, but akathisia and weight-related concerns were more common (Mohamed et al., 2017). This is why augmentation should be collaborative rather than automatic.
When Medication Alone Is Not Enough
Medication may reduce the biological intensity of depression, while therapy helps you change the behavioral and psychological patterns that keep symptoms going.
A randomized trial comparing behavioral activation, cognitive therapy, and antidepressant medication found that structured psychotherapy can be an effective treatment for major depression, particularly when it directly addresses avoidance and reduced activity (Dimidjian et al., 2006). For chronic depression, combined psychotherapy and medication also outperformed either treatment alone in a large randomized trial (Keller et al., 2000).
Consider adding therapy when you are dealing with:
- Persistent rumination or self-criticism
- Trauma-related symptoms
- Relationship stress
- Avoidance and loss of routine
- Difficulty managing suicidal thoughts
- Repeated depressive episodes despite medication
Medication, Therapy, TMS, or Spravato?
| Option | Main strength | Common limitation |
|---|---|---|
| Medication management | Systemic treatment that can address mood, anxiety, sleep, and concentration | Side effects, delayed response, and daily adherence |
| Depression therapy | Builds coping skills and addresses thoughts, behavior, trauma, and relationships | Requires regular participation and emotional effort |
| TMS | Noninvasive circuit-based treatment without typical antidepressant sexual or weight effects | Requires repeated clinic visits and may cause scalp discomfort or headache |
| Spravato/esketamine | May act more rapidly for selected treatment-resistant depression | Requires supervised administration, monitoring, and transportation planning |
TMS is an evidence-based option for some people who have not responded adequately to medication. BrainsWay Deep TMS is one of the most researched Deep TMS systems. Depending on the device, protocol, and settings, TMS sessions often run about 20–40 minutes; some theta-burst protocols may be as short as 3 minutes. A randomized trial of Deep TMS in treatment-resistant depression found higher response and remission rates with active treatment than sham treatment (Levkovitz et al., 2015).
Spravato, or intranasal esketamine, is administered under clinical supervision because it can cause temporary dissociation, sedation, dizziness, nausea, and blood-pressure elevation. In a randomized relapse-prevention trial, continuing esketamine plus an oral antidepressant reduced relapse compared with discontinuing esketamine in patients who had achieved stable response or remission (Daly et al., 2019). TMS and Spravato are not interchangeable, and neither is automatically “better.” Your psychiatric history, treatment response, medical conditions, preferences, and access all matter.
Self-Pay Care in New Haven
You do not have to wait for insurance coverage to seek help. Light-tunnel Behavioral Health Services Inc. serves self-pay clients with flexible care options, including:
- Transparent fees discussed before scheduling
- Psychiatric evaluations
- Medication management
- Therapy services
- In-person appointments in the New Haven area
- Telehealth appointments when clinically appropriate
- Superbills that you may submit to your insurer for possible out-of-network reimbursement
- Sliding-scale availability and flexible payment discussions when applicable
Self-pay care may also reduce or avoid insurance authorization delays, although coverage and reimbursement depend on your plan. Learn more about services, accepted insurance plans, or contact Light-tunnel Behavioral Health Services Inc. to discuss your options.
What to Do, and What to Avoid
Do:
- Tell your provider about every medication, supplement, and substance you use.
- Report any history of mania, hypomania, seizures, eating disorders, or medication reactions.
- Track sleep, energy, anxiety, appetite, sexual functioning, and daily performance.
- Ask how long to continue a medication after you begin feeling better.
- Discuss therapy or interventional treatment if symptoms remain disabling.
Avoid:
- Stopping an antidepressant suddenly without a tapering plan.
- Combining serotonergic medications or supplements without professional guidance.
- Assuming a medication has failed before an adequate trial has occurred.
- Ignoring new agitation, impulsivity, reduced need for sleep, or unusually elevated mood.
- Treating online medication comparisons as a substitute for a psychiatric evaluation.
Medical Safety Disclaimer and Emergency Resources
This article is for educational purposes only. It does not diagnose depression or recommend a specific medication, dosage, combination, TMS protocol, or Spravato treatment plan. Antidepressants require individualized evaluation and monitoring. Medication changes should be made with a qualified healthcare professional.
If you are in immediate danger, may hurt yourself or someone else, cannot stay safe, or are experiencing severe psychiatric symptoms:
- Call or text 988 for the Suicide & Crisis Lifeline.
- Call 911 or go to the nearest emergency department for an immediate emergency.
- Do not wait for a routine appointment during a crisis.
Continue the Series
Read the next post: Deep TMS vs. Traditional rTMS: Comparing Types of TMS Therapy for Depression in New Haven
References
Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
Rush, A. J., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
Clayton, A. H., et al. (2006). Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in two randomized, double-blind, placebo-controlled studies. Journal of Clinical Psychiatry, 67(5), 736–746. https://pubmed.ncbi.nlm.nih.gov/16841623/
Jacobsen, P. L., et al. (2015). Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. Journal of Clinical Psychiatry, 76(7), 963–970.
Dimidjian, S., et al. (2006). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. Journal of Consulting and Clinical Psychology, 74(4), 658–670. https://doi.org/10.1037/0022-006X.74.4.658
Keller, M. B., et al. (2000). A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine, 342(20), 1462–1470. https://doi.org/10.1056/NEJM200005183422001
Mohamed, S., et al. (2017). Effect of antidepressant switching vs. augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: The VAST-D randomized clinical trial. JAMA, 318(2), 132–145. https://doi.org/10.1001/jama.2017.8036
Levkovitz, Y., et al. (2015). Efficacy and safety of deep transcranial magnetic stimulation for major depression: A prospective multicenter randomized controlled trial. World Psychiatry, 14(1), 64–73. https://doi.org/10.1002/wps.20199
Daly, E. J., et al. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 76(9), 893–903. https://doi.org/10.1001/jamapsychiatry.2019.1189